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Abstract
Background: This study is to assess differences in periprocedural outcomes among diabetic and non-
diabetic patients treated with percutaneous coronary intervention (PCI) and rotational atherectomy (RA). 
Methods: Under assessment were 221,187 patients from the Polish Cardiovascular Intervention So-
ciety national registry (ORPKI) including all PCIs performed in Poland in 2015 and 2016. Data was 
extracted of 975 patients treated with RA — 336 (34.5%) diabetics and 639 (65.5%) non-diabetics. 
Periprocedural complications were defined as overall rate or particular complications such as deaths, 
no-reflows, perforations, dissections, cerebral strokes or bleedings. Multivariate analysis was performed 
to assess predictors of periprocedural complications. 
Results: The mean age was similar in diabetics and non-diabetics (70.9 ± 9.0 vs. 72.1 ± 9.9; p = 0.06).  
Diabetics were more often females (p < 0.01), with arterial hypertension (p < 0.01), kidney failure  
(p < 0.01) and prior myocardial infarction (p = 0.01). No significant differences were observed in  
overall or individual periprocedural complications and angiographic success was expressed as throm-
bolysis in myocardial infarction grade 3 flow after PCI. At baseline, de-novo lesions accounted for 
96.5% in diabetics and 99% in non-diabetics (p < 0.01), while overall rate of restenosis was 3.5% and 
1%, respectively (p < 0.01). Diabetes was an independent predictor of periprocedural complications in 
the overall group of patients treated with PCI (OR 1.11, 95% CI 1.04–1.194; p < 0.001). 
Conclusions: The negative impact of diabetes on the incidence of periprocedural complications and 
angiographic effectiveness in the group of patients treated with RA is mitigated in the comparison to the 
non-RA group. (Cardiol J 2020; 27, 2: 152–161)
Key words: percutaneous coronary interventions, rotational atherectomy, periprocedural 
complications, angiographic effectiveness, in-stent restenosis, diabetics, predictors, 
coronary artery calcifications
Introduction
Diabetes mellitus (DM) is among leading risk 
factors for coronary atherosclerosis and is related 
to specific imaging of coronary arteries including 
disseminated atherosclerosis and narrowed coro-
nary arteries [1, 2]. Individuals with DM are also 
at increased risk of coronary artery calcifications 
(CAC) which is subsequently related to increased 
risk of cardiovascular events [3]. Patients with DM 
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undergoing coronary arteries revascularization 
with percutaneous coronary interventions (PCI) 
or coronary artery bypass grafting operations 
(CABG) present higher restenosis and poorer long-
term survival rates than non-diabetic patients [4]. 
The optimal method of revascularization for dia-
betic patients with disseminated atherosclerosis is 
a subject of constant debate. One of the methods 
of intravascular treatment which allows patients an 
option to avoid surgical revascularization is rota-
tional atherectomy (RA). The results of previously 
published studies on groups of patients treated with 
PCI, not previously undergoing revascularization 
of coronary arteries, have provided inconclusive 
results. Despite differences in the angiographic 
images of the coronary arteries and the burden 
of accompanying diseases, some studies did not 
show differences in the efficacy and incidence of 
periprocedural complications between patients 
with and without diabetes, while the others showed 
a higher incidence of in-hospital deaths and nonfatal 
myocardial infarctions (MIs) [5, 6]. The availability 
of recently published research on RA in the drug-
eluting stent (DES) era, comparing periprocedural 
outcomes depending on the prevalence of diabetes, 
is very limited. One of the very few older studies, 
comparing periprocedural results of PCI with plain-
old balloon angioplasty (POBA) preceded by RA in 
groups of patients with and without DM, revealed 
that initial success rate was comparable between 
those two groups [7]. Nonetheless, the complica-
tion rates were higher in non-diabetics compared 
to diabetics except for the need of dialysis or pe-
ripheral vascular complications. 
Therefore, in the current study, the aim was 
to compare the angiographic effectiveness and 
complication rate in diabetics and non-diabetics 
treated with PCI and rotablation. 
Methods
Study population, design and definitions
Data from all patients who underwent PCI in 
Poland between January 2015 and December 2016 
were analyzed. Prospectively collected data on PCI 
practice in Poland were obtained from the ORPKI 
Polish national dataset, which is coordinated nation-
wide by Jagiellonian University Medical College in 
cooperation with the Association of Cardiovascular 
Interventions Polish Cardiac Society (AISN PTK). 
Database characteristics and data collection meth-
ods have previously been published [8–10]. Patients 
were categorized according to whether they were 
treated with RA and if they were diagnosed with 
diabetes or not. A flowchart of patients is presented 
in Figure 1. All indices recorded in the ORPKI da-
tabase are based on periprocedural data uploaded 
by the operator after each procedure. Therefore, 
they do not include all in-hospital complications, 
mainly those which occurred after the procedure 
until discharge from the hospital. Also, follow-up 
data was not collected after discharge due to a lack 
of patient IDs. The decision to perform the RA 
procedure was at the operators’ discretion at each 
center according to current European recommenda-
tions [11]. All clinical decisions, such as vascular 
access, thrombectomy, treatment with glycoprotein 
IIb/IIIa inhibitors or bivalirudin, were at the opera-
tors’ discretion. The definition of periprocedural 
complications including death, perforation, dissec-
tion, allergic reaction, cerebral stroke, puncture site 
bleeding, no-reflow or cardiac arrest remained to 
the operators’ personal preference and knowledge. 
The RA procedure was limited to one culprit artery, 
which was qualified for the procedure. Angiographic 
presentation refers to the general picture of coro-
nary arteries. 
Overall group of patients treated with
PCI (n = 221,187)
Rotablation
(n = 975; 0.44%)
Diabetes (+)
(n = 336; 34.5%)
Diabetes (+)
(n = 52,341; 23.8%)
Diabetes (–)
(n = 639; 65.5%)
Diabetes (–)
(n = 167,871; 76.2%)
Rotablation (–)
(N = 220,212; 99.55%)
Figure 1. Patient flowchart.
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Statistical analysis
All continuous variables were evaluated with 
the Kolmogorov-Smirnov test for distribution. Con-
tinuous variables are presented as mean ± stan-
dard deviation and median ± interquartile range. 
Categorical variables are presented as numeric 
values and percentages. Continuous variables were 
compared using the two-tailed Student t-test and 
the Mann-Whitney U-test, whereas categorical 
variables using the c2 test. Both, univariate and 
multivariate regression models for all complica-
tions were constructed in the group of patients 
treated with PCI but without RA. A model based 
on the retrograde correction method was created. 
Statistical significance was accepted at a 0.05 
level of probability. The statistical analyses were 
performed using Statistica 10.0 software (Dell 
Software, Inc., Round Rock, TX, USA). 
Results
General characteristics 
The frequency of diabetes was higher in the 
group of patients treated with RA compared to 
those without RA (34.5% vs. 23.8%; p < 0.0001; 
Fig. 1). The mean age was similar in diabetics and 
non-diabetics from the group of patients treated 
with RA (70.9 ± 9.0 vs. 72.1 ± 9.9; p = 0.06). 
Diabetics were more often women (p = 0.0008), 
those who suffered more often from arterial hy-
pertension (p < 0.0001), chronic kidney disease 
(p = 0.004) and prior MI (p = 0.01). Other con-
comitant diseases, previous cardiovascular inter-
ventions and smoking percentage did not differ 
significantly between groups. Also, the clinical 
presentation of coronary artery disease including 
stable angina, unstable angina, ST-segment eleva-
tion MI (STEMI), non-ST-segment elevation MI 
(NSTEMI) and others, did not differ between the 
diabetics and non-diabetics. Stable angina was more 
often a clinical presentation at baseline I patients 
treated with RA compared to the non-RA group. 
Also, patients treated with RA were previously 
more often treated due to coronary atherosclero-
sis and suffered from cardiac and cerebrovascular 
events. This is presented in Table 1.
Pharmacotherapy
Before admission to hospital, patients with 
diabetes were treated significantly more often 
with acetylsalicylic acid (p = 0.001), clopidogrel 
(p = 0.004) and ticagrelor (p < 0.0001). Pharma-
cotherapy in patients from RA and non-RA group 
according to diabetes is presented in Table 2. 
Procedural variables
Vascular access and location of culprit lesion 
was according to the type of coronary artery or 
bypass graft were similar in both groups. Both PCI 
of chronic total occlusions lesions (6.2% vs. 4.5%, 
p = 0.24) and bifurcations (11.6% vs. 6.2%) were 
performed more often in the group of diabetics in 
relation to non-diabetics, but only for bifurcations 
did it achieve statistical significance (p = 0.003). 
Single vessel disease was less frequent in diabet-
ics compared to non-diabetics (63.8% vs. 71.3%, 
p = 0.04), while multi-vessel disease with (12.3% 
vs. 8.9%, p = 0.15) and without left-main coro-
nary artery (LMCA) involvement (19.7% vs. 17.8; 
p = 0.53), as well as separate LMCA involvement 
(4.1% vs. 1.9%; p = 0.09), occurred in all subgroups 
but more often in diabetics compared to non- 
-diabetics, however, without statistical significance. 
Patients in RA group, in comparison to non-RA 
group were treated more often from femoral access, 
presented more often with more advanced athero-
sclerosis, were treated more often with DESs and 
underwent less often plain-old balloon angioplasty 
and/or failed angioplasty in both diabetics and non-
diabetics. This is presented in Table 3.
Culprit lesion characteristics
Patients with DM, presented de-novo lesions 
significantly less often compared to non-diabetics 
at baseline (96.5% vs. 99%, p < 0.01). De-novo le-
sions occurred significantly more often in patients 
from RA group compared to non-RA for diabetics 
and non-diabetics. However, diabetics presented 
restenosis significantly more frequently com-
pared to non-diabetics at baseline (3.5% vs. 1%, 
p < 0.0001), and this was mostly due to higher 
DES restenosis rate (2% vs. 0.4%, p < 0.0001). 
Also, the restenosis rate was higher in the group 
of patients treated without RA compared to the RA 
group for diabetics and non-diabetic. There were 
no patients treated due to in-stent thrombosis in 
patients treated with RA in diabetics and non-
diabetics. This is presented in Figure 2A–C. 
Angiographic effectiveness
Angiographic effectiveness was expressed 
as thrombolysis in myocardial infarction (TIMI) 
3 grade flow which was achieved after RA proce-
dure. Despite the fact that a prevalence of patients 
with TIMI 3 grade flow prior to RA procedure was 
greater in diabetics (62.9% vs. 51.7%, p = 0.0009), 
after treatment the TIMI 3 grade flow rate did 
not differ significantly between the two groups 
of patients treated with PCI and RA (97.3% vs. 
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Table 2. Pharmacotherapy.
Pharmacotherapy RA (+) P RA (–) P
Diabetes (+) Diabetes (–) Diabetes (+) Diabetes (–)
Before hospitalization
Acetylsalicylic acid 143 (42.5%) 204 (31.9%) 0.001 26,006 (49.7%)* 82,020 (48.8%)* 0.001
P2Y12 inhibitors:
clopidogrel 154 (45.8%) 233 (36.5%) 0.004 29,754 (56.8%)* 91,664 (54.6%)* < 0.001
ticagrelor 5 (1.5%) 9 (1.4%) < 0.001 2,454 (4.7%)* 8,666 (5.2%)* < 0.001
prasugrel 1 (0.3%) 0 (0%) 0.16 275 (0.5%) 889 (0.5%) 0.9
GP IIb/IIIa inhibitors 4 (3.0%) 13 (5.3%) 0.31 4,156 (9.7%)* 17,330 (12.5%)* < 0.001
Bivalirudin 0 (0%) 0 (0%) – 4 (0.007%) 13 (0.007%) 0.98
During PCI
Acetylsalicylic acid 244 (72.6%) 424 (66.3%) 0.04 9,174 (17.5%)* 27,712 (16.5%)* < 0.001
P2Y12 inhibitors:  
clopidogrel 149 (44.3%) 252 (39.4%) 0.13 21.881 (41.8%) 70,803 (42.2%) 0.13
ticagrelor 11 (3.3%) 37 (5.8%) 0.08 2.475 (4.7%) 7,836 (4.7%) 0.56
prasugrel 0 (0%) 1 (0.1%) 0.46 240 (0.4%) 765 (0.45%) 0.93
GP IIb/IIIa inhibitors 1 (0.3%) 6 (0.9%) 0.25 164 (0.31%) 678 (0.4%)* 0.003
Bivalirudin 1 (0.3%) 2 (0.3%) 0.96 132 (0.25%) 435 (0.26%) 0.78
Data are expressed as numbers (percentages). The c2 test was used for categorical variables; *p < 0.05, when particular variable in rotational 
atherectomy (RA) group differs from corresponding in non-RA group; GP — glycoprotein; PCI — percutaneous coronary intervention 
Table 1. Patient characteristics.
Clinical variables RA (+) P RA (–) P
Diabetes (+) Diabetes (–) Diabetes (+) Diabetes (–)
Age [years] 70.9 ± 9.0  
70 [65 ÷ 78] 
72.1 ± 9.9 
73 [65 ÷ 80]
0.06 69 ± 9.8 
69 [62 ÷ 76]
66.4 ± 11* 
66 [59 ÷ 75]
< 0.001
Gender (males) 207 (61.6%) 461 (72.1%) < 0.001 31,828 (60.8%) 117,644 (70.1%) < 0.001
Hypertension 299 (89.0%) 458 (71.7%) < 0.001 45,589 (86.9%) 111,162 (66.2%)* < 0.001
Prior cerebral stroke 17 (5.0%) 24 (3.7%) 0.33 2,993 (5.7%) 4,256 (2.5%) < 0.001
Prior MI 189 (56.2%) 309 (48.3%) 0.01 20,057 (38.3%)* 48,400 (28.8%)* < 0.001
Prior PCI 204 (60.7%) 364 (57.0%) 0.25 22,468 (42.9%)* 59,408 (35.4%)* < 0.001 
Prior CABG 55 (16.4%) 92 (14.4%) 0.41 4,541 (8.7%)* 9,404 (5.6%)* < 0.001
Smoking 51 (15.2%) 88 (13.8%) 0.55 8,172 (15.6%) 34,268 (20.4%)* < 0.001
Psoriasis 1 (0.3%) 0 (0%) 0.16 299 (0.57%) 569 (0.3%) < 0.001
Kidney failure 51 (15.2%) 58 (9.1%) 0.004 5,686 (10.9%)* 6,332 (3.8%) < 0.001
COPD 11 (3.3%) 18 (2.8%) 0.68 2,030 (3.87%) 9,404 (5.6%)* < 0.001
Clinical presentation before PCI:
Stable angina 178 (53.3%) 352 (55.7%) 0.47 15,828 (30.3%)* 44,694 (26.7%)* < 0.001
Unstable angina 70 (20.9%) 117 (18.5%) 0.36 16,124 (30.8%)* 49,406 (29.5%)* < 0.001
NSTEMI 39 (11.7%) 73 (11.5%) 0.95 10,557 (20.2%)* 30,447 (18.2%)* < 0.001
STEMI 45 (13.5%) 88 (13.9%) 0.84 9,361 (17.9%)* 41,620 (24.8%)* < 0.001
Others 2 (0.6%) 2 (0.3%) 0.51 412 (0.8%) 1,441 (0.8%) 0.11
Data are expressed as mean ± standard deviation and median ÷ interquartile range or numbers (percentages). The Student’s t-test was used 
for continuous variables and the c2 test was used for categorical variables; *p < 0.05, when particular variable in rotational atherectomy (RA) 
group differs from corresponding in non-RA group; CABG — coronary artery bypass grafting surgery; COPD — chronic obstructive pulmonary 
disease; MI — myocardial infarction; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention; 
STEMI — ST-segment elevation myocardial infarction
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96.9%, p = 0.76). However, it was higher when 
compared to the non-RA group of diabetics (97.3% 
vs. 93.3%, p = 0.003) and non-diabetics (96.9% vs. 
94.2%, p = 0.003). However, when compared with 
contingency tables, the distribution of TIMI classes 
after endovascular treatment was not significantly 
different between the group of patients treated with 
RA or without RA (p = 0.23 for non-diabetics and 
p = 0.11). This is presented in Table 4. 
Periprocedural complications
The overall complication rate did not differ 
significantly between diabetics and non-diabetics, 
in the RA group (2.38% vs. 2.34%, p = 0.97). It also 
did not differ between groups for particular com-
plications in the RA group: coronary artery per-
foration (1.2% vs. 0.8%; p = 0.52), cardiac arrest 
(0.6% vs. 0.6%; p = 0.95), allergic reaction (0.3% 
vs. 0.1%; p = 0.64), no-reflow (0.3% vs. 0.8%; 
p = 0.35) or puncture site bleeding (0.3% vs. 0.1%; 
p = 0.64). The overall complication rate was lower 
in the non-RA group compared to the RA group for 
diabetics (2.34 vs. 2.14, p = 0.36) and non-diabetics 
(2.38% vs. 1.85%, p = 0.76). Moreover, the overall 
complication rate was significantly higher in dia-
betics compared to non-diabetics in the non-RA 
group of patients (2.14 vs. 1.85, p < 0.0001). This 
is presented in Figure 3. Among independent pre-
dictors of an increased rate of overall complication 
in the group of patients treated with PCI without 
RA, it was thus found: diabetes (odds ratio [OR] 
1.11, 95% confidence interval [CI] 1.04–1.194; 
Table 4. Angiographic effectiveness.
TIMI grade flow At baseline P After PCI P
Diabetes (+) Diabetes (–) Diabetes (+) Diabetes (–)
PCI with rotablation 
0 27 (8.1%) 43 (7.0%) < 0.001 3 (0.9%) 2 (0.3%) 0.51
1 35 (10.5%) 104 (16.9%) 1 (0.3%) 4 (0.6%)
2 61 (18.4%) 150 (24.4%) 5 (1.5%) 13 (2.1%)
3 209 (62.9%) 318 (51.7%) 324 (97.3%)* 605 (96.9%)*
PCI without rotablation
0 8,928 (17.6%) 35,559 (22.1%) < 0.001 1,336 (2.6%) 3,528 (2.2%) < 0.001
1 6,339 (12%) 22,246 (13.8%) 585 (1.1%) 1,587 (1%)
2 9,748 (19.2%) 30,379 (18.8%) 1,491 (2.9%) 4,282 (2.6%)
3 25,650 (50.6%)# 72,938 (45.2%)# 47,287 (93.3%)* 151,791 (94.2%)*
Data are expressed as numbers (percentages). The c2 test was used for categorical variables; *p < 0.05, when the results of TIMI flow differs 
after PCI from that before PCI in diabetics and non-diabetics; #p < 0.05, when the results of TIMI flow differs between rotational atherectomy 
(RA) and non-RA group in corresponding groups assessed before and after PCI; TIMI — thrombolysis in myocardial infarction; PCI — percuta-
neous coronary intervention
Figure 2. A. The frequency of de-novo lesions in rotational atherectomy (RA) and non-RA group according to diabetes 
status before the procedure; B. The frequency of overall restenosis in RA and non-RA group according to diabetes 
status before the procedure; C. The frequency of in-stent thrombosis in RA and non-RA group according to diabetes 
status before the procedure.
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p < 0.001), age (OR 1.02, 95% CI 1.01–1.02; 
p < 0.001), female gender (OR 1.28, 95% CI 
1.12–1.3; p < 0.001), prior MI (OR 1.31, 95% CI 
1.21–1.43; p < 0.001), prior cerebral stroke (OR 
1.67, 95% CI 1.47–1.91; p < 0.001), kidney failure 
(OR 1.61, 95% CI 1.44–1.81; p < 0.001), acute coro-
nary syndrome (OR 1.659, 95% CI 1.151–1.817, 
p < 0.001) and psoriasis (OR 1.54, 95% CI 1.04–2.28; 
p = 0.04), while among predictors of decreased rate 
of procedural related complications patent culprit 
artery before PCI was noticed (OR 0.39, 95% CI 
0.37–0.42; p < 0.001) as well as a hypertension 
(OR 0.93, 95% CI 0.86–0.99; p < 0.05). 
Discussion
The main finding of the current study is that 
patients with DM treated with PCI and RA presents 
comparable periprocedural complication rates and 
angiographic success compared to patients without 
DM. While in the overall group of patients treated 
with PCI without RA, diabetics treated present 
poorer angiographic success and greater rate of 
periprocedural complications. Comparing out-
comes of DM patients in cases of PCI without RA 
and PCI with RA, it can be concluded that RA atten-
uates the negative impact of DM on the increased 
rate of periprocedural complications and poorer 
angiographic outcomes. Also, the rate of success-
ful PCI assessed as the percentage of POBA and/ 
/or failed PCI was significantly higher in the group 
of patients treated without RA compared to those 
treated with RA for diabetics and non-diabetics. 
Moreover, while in the group of non-RA patients 
PCI success expressed as POBA/failed PCI rate 
was significantly poorer in diabetics, in patients 
treated with RA it was poorer for non-diabetics. 
It has been almost 40 years since interven-
tional cardiologists began to be interested in factors 
affecting the results of RA treatment [12]. Cur-
rently, around 20% of patients referred for revas-
cularization procedures are diabetics. Because of 
current knowledge, CABG is treatment superior 
to PCI in patients with DM and advanced coronary 
artery disease, and is related to decreased risk of 
death and MI [13]. PCI is a potential treatment 
option in patients with less complex lesions [14]. 
It has been demonstrated that patients treated 
with PCI and DES present a significant reduction 
in target lesion revascularization when compared 
to PCI with bare metal stent [15]. Most of the 
published studies demonstrate that diabetes is 
also associated with an increased incidence of CAC 
and thrombus [3, 16]. Also, a large meta-analysis 
including 12,682 patients has proven that DM and 
hypertension predict the presence and extent of 
CAC in symptomatic patients [17]. However, not all 
authors demonstrated that DM is associated with 
increased CAC. For example, with the use of optical 
coherence tomography, Milzi et al. [18] revealed 
that decreased fibrous cup thickness overlying the 
necrotic lipid core, rather than CAC, contributes to 
increased plaque vulnerability observed in diabet-
ics. While some studies have shown that calcified 
nodules are among the least common etiology of 
plaque erosions in patients with acute coronary 
syndromes, a majority of them have demonstrated 
that patients with CAC treated with regular PCI 
belong to the group at significantly increased risk 
of adverse cardiovascular events in the follow-up 
period, especially other acute coronary syndromes 
[19, 20]. Patients with CACs are also at increased 
risk of stent thrombosis and ischemic target lesion 
revascularization at year 1, and remain at increased 
ischemic risk, irrespective of new generation DES 
[21, 22].
In the current study, the frequency of dia-
betes in the group of patients treated with RA 
was significantly higher when compared to those 
treated with PCI but without RA (34.5% vs. 23.8%, 
p < 0.0001). Similarly, the incidence of other 
comorbidities and women was higher in diabetics 
compared to non-diabetics and was higher in pa-
tients treated with RA compared to non-RA. The 
obvious consequence of this is a lower incidence 
of patients with single disease in favor of patients 
with multi-vessel disease and LMCA involvement 
in diabetics compared to non-diabetics. A similar 
relationship was observed for comparison between 
Figure 3. The overall periprocedural complication rate 
in the rotational atherectomy (RA) and non-RA groups 
according to diabetes status; PCI — percutaneous coro-
nary intervention.
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RA and non-RA group of patients. What is more, 
diabetic patients treated with PCI with RA had 
statistically significantly lower incidences of de-
novo lesions and higher frequencies of restenosis 
at baseline. In a previous publication, it was also 
confirmed that diabetes is an independent predic-
tor of restenosis in an overall group of patients 
treated with PCI [23]. Due to the fact that a per-
centage of patients with diabetes in the subgroup 
of RA patients was higher, this relationship was 
preserved. However, in the current study, a lower 
rate of restenosis in patients formed the RA group 
compared to the non-RA group and was related to 
a higher rate of de-novo lesions for both diabetics 
and non-diabetics. 
Despite all the above listed risk factors of car-
diovascular events related to diabetes, the incidence 
of overall periprocedural complications in the group 
of patients treated with PCI and RA was slightly 
greater in diabetics compared to non-diabetics and 
it did not reach statistical significance. Nonetheless, 
in the group of patients treated with PCI without 
RA the negative effect of diabetes translated into 
a significantly increased rate of periprocedural com-
plications and poorer angiographic effectiveness. 
An increased rate of periprocedural complications 
has been reported in patients with CAC, to which 
diabetes predisposes [24]. A higher frequency of 
periprocedural complications in the group of pa-
tients treated with PCI and RA in comparison to the 
group of patients treated with PCI without RA is not 
surprising, and it is the consequence of a number 
of factors such as RA itself, a selected group of pa-
tients with advanced atherosclerosis, which is usu-
ally a consequence of exposure to a larger number 
of risk factors for atherosclerosis. The frequency 
alignment of overall periprocedural complications in 
the RA group between diabetics and non-diabetics 
may, at least to some extent, be a consequence of 
a greater use of acetylsalicylic acid and P2Y12 inhibi-
tors before the procedure in diabetics, which may 
contribute to reducing the number of no-reflows, 
cardiac arrests and deaths.
Another, rather more influential factor seems 
to be RA as a procedure. The increased frequency 
of periprocedural complications and poorer angio-
graphic efficacy in patients with DM and CAC is 
mostly derived by difficulties with stent delivery, 
expansion, increased rate of coronary artery dis-
sections, perforations, no-reflows and following 
cardiac arrests, cerebral strokes and deaths, as 
well as puncture site bleedings. The RA procedure 
itself decreases the risk of culprit artery related 
complications and systemic complications result-
ing from them. This is followed by the fact that 
passages performed with a rotablator during the 
procedure decreases the amount of calcified debris 
and widens the artery lumen [11]. This permits, 
among others, easier delivery of the stent and its 
better expansion, while reducing the number of 
complications. On the other hand, it was shown 
that RA is associated with a greater frequency of 
coronary perforations, but this factor occurred in 
both of the groups compared [8].
The results of previously published studies 
regarding the relationship between diabetes with 
acute results of PCI indicate an insignificantly 
lower incidence of periprocedural complications 
assessed as at least one major complication (death, 
MI, emergency bypass surgery or abrupt closure) 
in the group of diabetics compared to non-diabetics 
in patients treated with PCI and RA. This number 
is insignificantly higher in the case of diabetics 
compared to non-diabetics in the non-RA group [7]. 
Furthermore, long term results were poorer for 
diabetics in RA and non-RA patients [7]. Similar 
acute results were obtained in the present work, 
where the overall periprocedural complication rate 
was greater in diabetics compared to non-diabetics 
in non-RA patients. Additionally, diabetes was also 
found to be an independent predictor of peripro-
cedural complications in the non-RA group. This 
difference disappears and ceases to be statistically 
significant in the population of patients treated 
with PCI and RA. A similar relationship of DM and 
outcomes of RA treatment was presented in the 
analysis published by Mak and Faxon [25]. They 
underlined no significant influence of diabetes on 
periprocedural complication rate in patients treated 
with RA, however, they found at least some evi-
dence of a negative effect of diabetes on clinical out-
comes during follow-up in patients treated with PCI 
and PCI with RA [26]. Whereas in-hospital adverse 
outcomes, long-term mortality and the need for re-
peat revascularization procedures were reported in 
the era of POBA to be higher among diabetics [27, 
28]. In the years of the initial experiments, when 
the only treatment method was POBA, the results 
for diabetics were significantly worse, while the 
current primary treatment method is PCI followed 
by DES implantation, which can affect the gap be-
tween diabetics and non-diabetics. Nevertheless, 
more recently published analysis also depicts the 
strong effect of diabetes on restenosis rate in pa-
tients after PCI [15, 29].
In the presented study, the angiographic ef-
fectiveness assessed as the percentage of patients 
with patent coronary artery after PCI (TIMI 3 
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grade flow) was similar in diabetics compared to 
non-diabetics in patients treated with PCI and RA. 
Similar results have been published previously by 
other authors. Despite visible differences in the 
mean age, gender, the severity of coronary athero-
sclerosis and concomitant diseases, procedural suc-
cess rates were comparable between patients with 
and without DM [27, 28]. In the current study, the 
procedural effectiveness was significantly lower 
for both diabetics and non-diabetics in the non-
RA group compared to the RA group. Moreover, 
diabetics from the non-RA group, as in the case 
of periprocedural complications, presented lower 
procedural effectiveness when compared to non-
diabetics. There are several reasons which can be 
attributed to the cause of those differences. One 
of the reasons is that the group of patients treated 
with PCI but without RA included chronic total 
occlusions, while patients in the group treated 
with RA included selected patients, where it was 
possible to cross the lesions with a rotawire. This 
is reflected in the percentage share of patients 
qualified for PCI procedures, where the percentage 
of patients with an occluded vessel (TIMI 1 and 
2) was significantly larger, both for diabetics and 
non-diabetics in the non-RA group compared to the 
RA group. Moreover, as mentioned above, due to 
burr passages, the RA itself widens coronary artery 
lumen enabling better stent expansion, which un-
doubtedly improves the angiographic effectiveness. 
Limitations of the study
First of all, this study was based on the nation-
wide volunteer registry rather than a prospective 
randomized clinical trial. This tends to decrease 
and underestimate the detection of periprocedural 
complication rate and other crucial variables which 
are dependent on a subjective assessment of an 
operator, despite the large overall interventional 
volume included in the present analysis. Also, the 
assessment of blood flow in the target artery us-
ing the TIMI scale is subjective and depends on 
individual operators, despite the fact that a large 
number of procedures can significantly reduce this 
effect. Furthermore, the current analysis does not 
include all in-hospital complications, which certain-
ly weakens its value. Nonetheless, the uncountable 
advantage of the current study is that the results 
are closer to real life rather than to randomized 
clinical trials and show clinical data depicting the 
results of RA in diabetics in Central Europe. 
Conclusions
The negative impact of diabetes on the in-
cidence of periprocedural complications and an-
giographic effectiveness in the group of patients 
treated with RA is mitigated in comparison to the 
non-RA group.
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